April 1 - 5, 2017
Walter E. Washington Convention Center
Washington, D.C., USA
Abstract submission deadline: Thursday, November 17
Advance registration deadline: Sunday, January 29
American Association for Cancer Research (AACR) is accredited by the
Accreditation Council for Continuing Medical Education (ACCME) to
provide continuing medical education activities for physicians.
Credit Designation StatementThe AACR has designated this live activity for a maximum of 44.75 AMA PRA Category 1 Credit(s)TM. Physicians should only claim credit commensurate with the extent of their participation in the activity.
certification for individual sessions may vary, dependent upon
compliance with the ACCME Accreditation Criteria. The final number of
credits may vary from the maximum number indicated above.
Claiming (CME) CreditPhysicians and other health care professionals seeking AMA PRA Category 1 Credit(s)TM for
this live continuing medical education activity must complete the CME
Request for Credit Survey (will be included, below) by Wednesday, May 17, 2017.
Certificates will only be issued to those who complete the survey.
Statement of Educational Need, Target Audience, and Learning ObjectivesWith the accelerating
pace of discoveries in the basic, translational and clinical sciences, due in
large part to the advent of new technologies and also our increased
understanding of the interplay between the immune system and cancer, cancer
researchers are making rapid progress that is having significant patient
benefit. By bridging the gap between what physicians understand about cancer
biology and the clinical applications, this meeting aids basic researchers,
physicians, and clinician-scientists in obtaining, synthesizing, and
integrating the most cutting-edge research. This exposure is essential for the
implementation of best practices, such as the most current molecular-based
tests to aid in the diagnosis, treatment, and prevention of cancer. Further,
facilitating the interface between physicians and scientists will increase
knowledge of the epidemiological implications of cancer incidence and the
contributions of laboratory research to drug development as well as patient
care; transform the design and conduct of clinical research protocols; and
create a forum for the rapid translation of laboratory research findings from
“bench-to-bedside” for the benefit of improving patient outcomes.Despite the tremendous
progress in the field, cancer continues to be an enormous public health
challenge worldwide, accounting for one in every seven deaths that occur around
the world. In the United States (U.S.) alone, it is predicted that 595,650
people will die from some form of cancer in 2016, making it the second most
common cause of death after heart disease.
One of the challenges we face is that cancer is comprised of more than
200 different diseases. For many of the
most commonly diagnosed cancers in the U.S.—including colorectal, lung, and
prostate cancer—incidence has been declining for more than a decade. However, incidence of other forms of
cancer—including melanoma and kidney, liver, pancreatic and childhood
cancer—have been on the rise. Overall five-year relative survival rates for
U.S. patients vary widely depending on the form of cancer and the stage at
which it is diagnosed. Incidence and survival rates are also impacted by the
cancer health disparities that exist in certain segments of the U.S.
population. This conference
will bring together investigators from the basic, translational, and clinical
disciplines and provide them with a venue to discuss their recent advances,
test new hypotheses, and establish new collaborations. In order to have widespread implementation of
the most current, approved molecular-based tests to aid in the diagnosis,
treatment and prevention of cancer, it is critical to bridge the gap between
what physicians understand about cancer biology and its application to clinical
oncology. As the incidence of cancer
continues to increase, the fields of cancer prevention and early interception
offer unprecedented opportunities to decrease the worldwide burden of cancer.
After participating in this CME activity, physicians should be able to:
1. Recognize the technological advances and tools being used to accelerate progress in cancer research and improve early detection and early intervention, with the ultimate goal of extending patients' lives and improving their quality of life.
is the policy of the AACR that the information presented at AACR CME
activities will be unbiased and based on scientific evidence. To help
participants make judgments about the presence of bias, the AACR will
provide information that Program Committee members and speakers have
disclosed about financial relationships they have with commercial
entities that produce or market products or services related to the
content of this CME activity. This disclosure information will be made
available in the Program/Proceedings of this conference.
Acknowledgement of Financial or Other SupportThis activity is supported by grants and will be disclosed at the activity.
Questions about CME?Please contact the Office of CME at 215-440-9300 or firstname.lastname@example.org.